Abstract Incidental Lewy body disease (ILBD) is the term used when Lewy bodies are found in the nervous system of subjects without clinically documented parkinsonism or dementia. The prevalence of ILBD in the elderly population has been estimated at between 3.8 and 30%, depending on subject age and anatomical site of sampling. It has been speculated that ILBD represents the preclinical stage of Parkinson's disease (PD) and/or dementia with Lewy bodies (DLB). Studies of ILBD could potentially identify early diagnostic signs of these disorders. At present, however, it is impossible to know whether ILBD is a precursor to PD or DLB or is just a benign Wnding of normal aging. We hypothesized that, if ILBD represents an early stage of PD or DLB, it should be associated with depletion of striatal dopaminergic markers. Eleven subjects with ILBD and 27 control subjects were studied. The ILBD subjects ranged in age from 74 to 96 years (mean 86.5) while the control subjects' age ranged from 75 to 102 years (mean 86.7). Controls and subjects did not diVer in terms of age, postmortem interval, gender distribution, medical history conditions, brain weight, neuritic plaque density or Braak neuroWbrillary stage. Quantitative ELISA measurement of striatal tyrosine hydroxylase (TH), the principal enzyme for dopamine synthesis, showed a 49.8% (P = 0.01) reduction in ILBD cases, as compared with control cases. The Wnding suggests that ILBD is not a benign condition but is likely a precursor to PD and/or DLB.
Introduction
Incidental Lewy body disease (ILBD) may be deWned as the presence of Lewy bodies in the absence of clinically documented parkinsonism or dementia. The prevalence of ILBD in the elderly population increases with age. An early prevalence estimate, based on paraYn-sections stained with hematoxylin and eosin, found ILBD to be present in 3.8% of people in the 6th decade, rising to 12.8% by the 9th decade [20] . Subsequent estimates, performed using -synuclein immunohistochemistry to detect Lewy bodies and neurites, have found ILBD in 16% [42] , 17% [8] , 26% [34] and 30% [26] of aged subjects. The diVerences between studies may be due to diVering immunohistochemical methods, diVering subject ages and diVering sampling sites. Although Parkinson's disease (PD) is generally considered a disease of the central nervous system (CNS), it has long been known that Lewy bodies may also be found in the peripheral autonomic nervous system in PD subjects [15, 18, 36, 37, 46, 49] . Recent studies using immunohistochemical staining for -synuclein have found that the peripheral autonomic nervous system is a common site of aVectation in ILBD.
It has been speculated that ILBD represents the preclinical stage of PD and/or dementia with Lewy bodies (DLB). If this were true, studies of ILBD could identify early clinical or pathological signs that could be used to diagnose PD and/or DLB much earlier than is presently possible. Due to the involvement of the olfactory bulb and peripheral autonomic nervous system in ILBD, such signs might consist of a constellation of autonomic and olfactory dysfunction. Both olfactory dysfunction and constipation have already been reported to be statistically associated with ILBD [2, 41] . However, at present, it is impossible to know whether ILBD is a precursor to PD or DLB or is just a non-progressive benign Wnding of normal aging. We hypothesized that, as depletion of the dopaminergic nigrostriatal system is a deWning and pathogenic feature of PD and DLB, its presence in ILBD would suggest that ILBD is not a benign disorder but a probable early stage of one or the other.
Materials and methods

Human subjects
The study took place at Sun Health Research Institute (SHRI), which is part of a non-proWt, community-owned and operated health care provider located in the Sun Cities retirement communities of northwest metropolitan Phoenix, Arizona. Sun Health Research Institute and the Mayo Clinic Arizona are the principal member institutes of the Arizona Parkinson's Disease Consortium. Brain necropsies were performed on elderly subjects who had volunteered for the SHRI Brain Donation Program. The Brain Donation Program has been approved by the Institutional Review Board of Sun Health Research Institute. Subjects were chosen by searching the Brain Donation Program Database. Subjects with ILBD were deWned as those that had Lewy bodies on neuropathological examination but did not have a clinical diagnosis of parkinsonism or dementia. Control subjects were chosen based on the absence of Lewy bodies, parkinsonism and dementia. Additionally, both ILBD and control subjects were chosen on the basis of availability of fresh-frozen striatum for biochemical analysis. Subjects were clinically characterized by review of medical records, self-report and interviews with spouses and/or caregivers. As part of the Brain Donation Program's standard protocol, private medical records of 2 years are obtained from the subjects' private physicians, both at the time of enrollment (for those prospectively enrolled) and at the time of death. Subjects who sign up prospectively (before death) Wll out a questionnaire in which they (or their spouses or caregivers) are asked to report any signiWcant neurological conditions. Additionally, at the time of death, a telephone interview is conducted with the spouse or caregiver, in which they are asked whether the subject was mentally capable, demented or had Alzheimer's disease. If they were demented or had Alzheimer's disease, they are asked as to when that diagnosis was Wrst given. They are also asked if the subject had any shaking or jerking movements and if so, to describe those and state as to when they were Wrst observed. They are also asked to state all of the subject's known medical diagnoses. Since 1997, a subset of subjects has received standardized cognitive and neuromotor assessments, including the Mini Mental State Examination (MMSE) and UniWed Parkinson's Disease Rating Scale (UPDRS).
Tissue processing and analysis
The cerebrum was cut in the coronal plane into 1-cm-thick slices while the brainstem was sliced axially at 1-cm intervals. The entire brain was then divided sagittally into left and right halves. The slices from the right half were frozen between slabs of dry ice while the slices from the left half were Wxed by immersion into buVered 4% formaldehyde for 48 h at 4°C. Following cryoprotection in ethylene glycol and glycerol, selected cerebral and midbrain blocks were cut into sections of 40 m thickness on a sliding freezing microtome. Additionally, a standard set of brainstem, cerebellar and cerebral blocks were embedded in paraYn and cut at 6 m. Free-Xoating 40-m sections were stained with H&E, thioXavine S, Campbell-Switzer and Gallyas methods. ParaYn sections were stained with H&E and a selected set was stained immunohistochemically for -synuclein (clone LB509, Chemicon), after pretreatment with 90% formic acid. Additionally, selected 40-m sections were stained immunohistochemically for -synuclein, using a separate antiserum raised against -synuclein phosphorylated at serine 129 [19] . The immunoperoxidase method employed an avidin-biotin-horseradish peroxidase complex (ABC); the method has been generally described in a prior publication [5] . Neuritic plaques and neuroWbrillary tangles were staged according to CERAD, Braak and NIA-Reagan criteria [1, 9, 35] . Lewy bodies and Lewyrelated neurites ( Fig. 1) were identiWed with H&E, thioXavine S and immunohistochemical methods and staged according to the Dementia with Lewy Bodies Consortium and criteria set forth by Braak et al. [11, 33] .
Frozen putamen from the level of the globus pallidus pars interna was dissected out and analyzed quantitatively for TH using an ELISA. This site has been reported to show the earliest loss of striatal dopamine in PD [6] . Samples were solubilized in four volumes of extraction buVer composed of 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1% Triton X 100, 0.2% SDS and protease inhibitors (Roche Biochemicals, Indianapolis, IN, USA), and centrifuged at 13,000 rpm for 15 min; the supernatant was used to measure TH protein levels. Prior to analyses, samples were diluted to contain equal amounts of protein (10 g/100 l). The TH ELISA consisted of an aYnity-puriWed rabbit antibody to tyrosine hydroxylase (Covance Inc, Berkeley, CA, USA) to coat the plates (Wnal concentration 0.5 g/ml) as capture reagent, and a mouse monoclonal antibody to TH (Sigma-Aldrich, St. Louis, MO, USA) as detection reagent (1:6,000 dilution, Wnal concentration). The amounts of bound antibody-complexes were detected using a horseradish peroxidase-labeled anti-mouse immunoglobulin, reaction with ELISA substrate (R and D Systems, Minneapolis, MN, USA), and measurement of the absorbance in each well at 450 nm wavelength. The concentration of TH in each sample was determined in comparison to standard curves constructed using known amounts of recombinant TH (kindly provided by Dr. Paul Fitzpatrick, Texas A&M University, TX, USA). A number of the protein extracts of putamen that had been analyzed by ELISA were also assessed qualitatively by standard Western blot methodology. Membranes were probed with the TH antibody used for ELISA capture, which was detected using an HRPlabeled anti-rabbit immunoglobulin and reaction with Supersignal Dura chemilumescent substrate (Pierce Chemical Co, Rockland, IL, USA) followed by imaging on an Fluorochem 8900 imaging system (Alpha Innotech, San Leandro, CA, USA).
Statistical analysis
Statistical analyses consisted of unpaired, two-tailed t-tests for comparisons of continuous variables. The Mann-Whitney U-test was used for comparisons of discontinuous variables. Semi-quantitative scores for neuritic plaques (none, sparse, moderate, frequent), neuroWbrillary tangles (Braak stages I-VI) and Lewy bodies (DLB Consortium stages brainstem predominant, limbic and neocortical; Braak stages I-VI) were converted to numerical equivalents (0, 1, 2, 3 for plaques; 0-6 for tangles; 0-3 for DLB Consortium Lewy body score; 0-6 for Braak Lewy body stage) prior to analysis. Prevalence of medical history conditions were compared using Chi-square tests while MMSE and UPDRS scores were compared using unpaired, two-tailed t-tests.
Results and discussion
Using the search criteria described, 11 subjects with ILBD and 27 control subjects were identiWed. The ILBD subjects ranged in age from 74 to 96 years (mean 86.5; SD = 5.9) while the control subjects ranged from 75 to 102 years (mean 86.7; SD = 7.4). Controls and ILBD cases did not diVer in terms of age, postmortem interval, gender distribution, brain weight, neuritic plaque density or Braak neuroWbrillary stage (Table 1) . A subset of subjects had received standardized cognitive (seven ILBD and seven control subjects) and neuromotor (six ILBD and six control subjects) assessments. The groups did not diVer signiWcantly in their MMSE or UPDRS (UPDRS: Part III-Motor Scores). The mean MMSE scores were 27.0 (SD 2.2) and 28.1 (SD 1.9) for ILBD and control cases, respectively, while the mean UPDRS scores were 13.7 (SD 12.0) and 20.4 SD (7.2), respectively. Six ILBD cases were rated as brainstem predominant and Wve were rated as limbic or transitional, using the DLB Consortium system. Lewy body stage according to the Braak system ranged from 2 to 4, with 6 cases rated as stage 2 or 3 and 5 rated as stage 4 (see Table 3 ).
Review of medical records in all 11 ILBD cases and 25 control cases (two control cases did not have medical records available) showed that the average time between the last physician's note and death was 5.4 months (SD 8.4). The most common medical history conditions in ILBD cases were supraventricular arrhythmia, hypertension, falls, dysphagia and depression (Table 2) . On comparison with the control group, however, none of these were signiWcantly diVerent on Chi-square analysis.
Quantitative measurement of striatal TH by ELISA (Fig. 2) showed a signiWcant reduction in ILBD cases to 49.8% of control values (ILBD mean = 17.5 ng/mg protein, SD = 14.1; control mean = 35.1 ng/mg protein, SD = 20.0; P = 0.01) ( Table 3) .
The major Wnding of this report is that ILBD cases have signiWcant reductions of striatal TH concentrations as compared with age-similar normal elderly subjects. As TH is a dopaminergic marker, the results indicate that the nigrostriatal dopaminergic system is signiWcantly depleted in these individuals, suggesting that ILBD is not a benign condition but is likely a precursor to PD and/or DLB. This result contrasts with that of an earlier study, which found no diVerence in striatal dopamine levels between control and ILBD cases [16] . It is possible that the diVerence between ILBD cases and controls in this study may have been obscured by the long PMIs (means were 14 and 21 h for controls and cases, respectively) for the 12 cases they studied. Although the authors found no correlation between PMI and dopamine levels for their subjects, a larger study of 30 cases [13] reported a signiWcant inverse correlation between PMI and striatal dopamine concentrations (correlation coeYcient ¡0.53, P < 0.01). Alternatively, as we measured TH rather than dopamine, it is possible that a decreased TH protein level might be compensated for, in the ILBD striatum, by increased TH functional activity, decreased dopamine catabolism, or other mechanisms. It has generally been established, through both human and primate studies, that parkinsonian symptoms occur when striatal dopaminergic markers are 80% depleted compared to age-similar normal subjects [7, 23] . The Wnding that ILBD subjects have approximately 50% reductions of striatal TH is therefore consistent with their lack of clinically detectable parkinsonian signs. The results for TH support previous studies showing that substantia nigra pigmented neuron numbers are depleted in ILBD, falling between control and PD subjects [17] .
It has been reported that striatal pathology may diVerentiate Parkinson's disease with dementia from dementia with Lewy bodies [27] . We stained the striatum of all cases with the Campbell-Switzer method for amyloid and found 7 of 27 cases were positive in the control subjects while 6 of 11 ILBD cases were positive. The diVerence did not reach the signiWcance level on a Chi-square test (P = 0.09), but is suggestive of a greater likelihood for striatal amyloid deposition in ILBD.
Study of ILBD subjects may allow detection of non-parkinsonian clinical features that would be predictive of the development of PD and/or DLB. It has been suggested, for example, that olfactory dysfunction, depression and autonomic nervous system dysfunction may be predictive for subsequent PD [3, 22, 29] . Olfactory bulb and peripheral autonomic nervous system synucleinopathy, are very common if not universal Wndings in PD [10-12, 14, 37, 39, 46, 48, 49] . Olfactory dysfunction and olfactory bulb synucleinopathy have been reported to be present in ILBD cases and hence smell tests and/or olfactory bulb biopsy may be useful for early diagnosis in PD and/or DLB.
Review of the private medical records of the ILBD and control cases did not reveal signiWcant disease associations. As there are multiple reports of synucleinopathy of the cardiac sympathetic innervation in PD and DLB [4, 21, 25, 32, 43, 45, 47] , an increased prevalence of cardiac arrhythmias in ILBD might have been predicted. Similarly, depression has been suggested to be a common early symptom in PD [24, 31] . However, although supraventricular arrhythmias and depression were common in our ILBD cases, they were also common in our control cases. Hypertension, which has been reported to be less common in PD [38, 44] was common in our ILBD cases but was somewhat more common in the control cases. Dysphagia has also been reported to be a potential early marker for PD [28, 30, 40] but this was present to a similar degree in both our ILBD and control subjects. Falls are usually considered a later-stage feature of PD [50, 51] , so it was surprising to see this as a common Wnding in ILBD cases. Falling was, however, also common in the control cases, suggesting that this is age-related. The lack of diVerences between ILBD subjects and controls in our study may be due to their advanced ages or to the small sample size, but it appears from this study that there are no large medical history diVerences between the groups. Larger studies, with the inclusion of standardized antemortem clinical assessments, are needed to fully determine whether there are any speciWc disease associations with ILBD. 
